

ADVERSE DRUG REACTIONS (ADR)

Group : 5

Dr. Pranabandhu Das

Dr. Jayaprada R.

Ms. Radhika K.

Ms. Bhargavi G.

Ms. Lakshmi Devi

Ms. Bhagyasree G.

Mr. Prakash B.

Mr. Bannerjee K.

Reviewed By :

Dr. Lallu Joseph

Dr. Saravana Kumar

Ms. Devasri Chatterjee

MISSION STATEMENTS

SVIMS HOSPITAL

స్విమ్స్ వైద్యశాల

OUR MISSION

మన లక్ష్యం

• **Serve the underserved**

ప ఆధారములేని పేదలకు సేవ చేయడం.

• **Improve patient health outcomes through focus in quality & patient safety**

నాణ్యమైన మరియు భద్రతతో కూడిన వైద్యం అందించడం ద్వారా రోగి ఆరోగ్య పరిస్థితిని మెరుగుపరచడం.

• **Increase patient satisfaction & enhance stakeholder experience**

రోగి సంతృప్తిని పెంచడం ద్వారా భాగస్వాముల అనుభవాన్ని రెట్టించు చేయడం.

• **Decrease cost & waste in healthcare delivery**

వైద్యం అందించడంలో ఖర్చుని వృధాని తగ్గించడం.

SVIMS :OUR MISSION


Serve the Unserved

To Improve Patients health outcome through focus on Quality and Patient Safety.

To Increase Patients Satisfaction and Enhance Stake holder's Experience

To Decrease Cost and Waste in healthcare delivery

MISSION CENTERED APPROACH



MISSION

POLICY

**(NABH Chapters
& Standards)**

PROCEDURE

(Objective Elements)

ADVERSE DRUG REACTION (ADR)

- CHAPTER -3/10, **(MOM)**
 - STANDARD-8 /13 (**Near misses, medication errors and Adverse Drug Events** are reported and analysed)

POLICY

- **ADRs** are reported and analyzed and appropriate corrective and preventive actions to be taken

PROCEDURES

- **Objective Elements**
- A. ADRs are defined. *
- Which are in consonance with best practices.

➤ **SIDE EFFECT:** Any unintended effect of a pharmaceutical product at normal dose which is related to the pharmacological properties of the drug.

(ACCEPTABLE and NON DELETERIOUS)

➤ **ADVERSE EVENT:** Any untoward medical occurrence that may present during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with this treatment. (UNACCEPTABLE and DELETERIOUS)

➤ **ADVERSE DRUG REACTION (ADR):** A response to a drug which is Noxious and Unintended *occurs at doses normally used in man* for the prophylaxis, diagnosis, or therapy of disease, or for the modifications of physiological function. (WHO, 1972)

SERIOUS ADVERSE DRUG REACTION

Serious adverse reaction is defined as one in which the patient outcome is

- **Death**- if the patient died due to adverse event
- **Life-threatening**- if patient was at substantial risk of dying at the time of the adverse event.
- **Hospitalisation/prolonged**- if the adverse event caused hospitalisation or increased the hospital stay of the patient.
- **Disability**- if adverse event resulted in a substantial disruption of a person's ability to conduct normal life functions.

Contd...

- **Congenital anomaly**- if exposure of drug prior to conception or during pregnancy may have resulted in an adverse outcome in the child.
- **Required intervention or prevent permanent impairment/damage**- if medical or surgical intervention was necessary to preclude permanent impairment of a body function, or prevent permanent damage to a body structure.

Drug group	No (%) ADRs	Top ten causative drug groups	Rank by frequency of use of drugs	Drugs (number of ADRs for each causative drug)	Adverse drug reactions
Loop diuretics	151 (20.6)	1	14	Furosemide (123), bumetanide (40)	Electrolyte disturbances, gout, hypotension, ileus, nausea, renal failure
Opioids	118 (16.1)	2	1	Morphine (88), tramadol (53), dihydrocodeine(10), fentanyl (8), codeine(8), oxycodone (7), pethidine (2)	Confusion, constipation, sedation, dizziness, respiratory depression, hallucinations, ileus, hypotension, itching, nausea, rash, dependence
Systemic corticosteroids	87 (11.9)	3	18	Prednisolone (67), dexamethasone (14), hydrocortisone (11), methylprednisolone (1), fludrocortisone	Electrolyte disturbances, increased INR, bleeding, hallucination, hyperglycemia, fracture, hypertension,

Beta-agonists (inhaled)	85 (11.4)	4	12	Salbutamol (85), terbutaline (4), salmeterol (3)	Electrolyte disturbances, nausea, tachycardia
Penicillins	66 (9.0)	5	6	Co-amoxiclav (34), amoxicillin (24), flucloxacillin (15), benzylpenicillin (7), penicillin v (1), ampicillin (1)	CDT, bleeding, rash, nausea, diarrhoea, increased INR, candidal infection

Adverse drug reaction	No associated patient deaths	Drugs (number of deaths)	Avoidability (definite, possible, unavoidable)
Renal failure	7 [*]	Gentamicin (1), bumetanide, valsartan (1), bumetanide, furosemide, spironolactone, ramipril (1), allopurinol, ceftriaxone, furosemide (1), diclofenac (1), furosemide, spironolactone (1), bumetanide,	1 definite, 2 possible, 4 unavoidable
<i>Clostridium difficile</i> infection	5 [*]	Ceftriaxone and ciprofloxacin and gentamicin (1), ceftriaxone, ciprofloxacin, lansoprazole (1),	3 possible, 2 unavoidable

GI Bleed	2	Dalteparin, diclofenac (1), aspirin, dalteparin, dipyridamole, enoxaparin (1)	1 definite, 1 possible
Ischaemic bowel	1	Glypressin (1)	

- **B.** Documented procedure outlines the process for identifying, documenting, reporting, analyzing and taking action
- These are reported within a specified time frame.
- **Interpretation: The organization shall define the timeframe for reporting once.**

C. They are collected and analyzed.

(All these incidents are analyzed regularly by the multi-disciplinary committee. The analysis shall be completed in a defined time frame.)

- **D.** Corrective and/or preventive action(s) are taken based on the analysis where

Pharmacovigilance

Pharmacovigilance is the science and activities dealing with

- Detection
- Assessment
- Understanding
- Prevention



of adverse drug reactions or any other possible drug related problems (WHO 2002)


PHARMACOVIGILANCE PROGRAMME OF INDIA

- In July, 2010, under the ministry of Health and family welfare, a nation-wide revised ADR monitoring programme was launched and named as **Pharmacovigilance Programme of India (PvPI)** to improve ADR monitoring in the country,
- Initially, under this National programme, All India Institute of Medical Sciences, New Delhi was the **National Coordination Centre (NCC)** and in April, 2011, it was shifted to Indian **Pharmacopoeia Commission (IPC)**, Ghaziabad.

INTERNATIONAL COLLABORATION CENTRE

WHO-UMC


SWEDEN



NATIONAL COORDINATION CENTRE

IPC

GHAZIABAD



ADVERSE DRUG REACTION MONITORING CENTRE

SVIMS,SPMC(W)

TIRUPATI

TIMELINE

- Expedited reporting of serious ADR's is required as soon as possible, but in no case later than **24 hours** of initial receipt of information by the health care provider.

PROCEDURE

NURSE

Observe, Report, Document and Begin ADR report

- Staff nurse who identifies an ADR should immediately **inform the on duty doctor.**
- Staff nurse should also assess the patient and if the event is significant or with the potential to cause patient harm, should provide **immediate care to the patient.**
- Staff nurse should be aware of side effects/ADR of various drugs **to anticipate and monitor accordingly.**

Contd..

- The staff nurse should provide the treatment as **per directive from the doctor**.
- The staff nurse should inform the senior nurse immediately.
- The patient should be **monitored cautiously by** a staff nurse till the patient is clinically stabilized.
- Staff nurse **should document the events in the nursing notes**.

RESPONSIBILITIES

DOCTOR

Observe, assess, prescribe, document and complete ADR report

- In case of ADR, the **drug should be stopped** immediately and the doctor after evaluating the patient should advise the treatment as appropriate.
- The **doctor reports the ADR to the consultant** immediately and obtains his advice.
- The **doctor should document the events in progress notes and discharge summary.**
- The on duty doctor should **fill the suspected adverse drug reaction reporting form and submit** to the Pharmacovigilance committee or Pharmacovigilance associate for further evaluation of the report.

PREVENTION

- Avoid all inappropriate use of drugs in the context of patient's clinical condition.
- Use appropriate dose, route and frequency of drug administration based on patient specific variables.
- Elicit and take into consideration previous history of drug reactions`/Allergies.
- Rule out possibility of drug interactions when more than one drug prescribed.
- Adopt correct drug administration technique.

Benefits of ADR Reporting

1. Assesses the safety of drug therapies, especially recently approved drugs.
2. Provides updated drug safety information to healthcare professionals and other stakeholders.
3. Measures the economic impact of ADR prevention.
4. Regulatory action on the basis of ADR reports to ensure patient's safety

Suspected Adverse Drug Reaction Reporting Form

This form is divided into four sections:

- A. Patient Information**
- B. Suspected Adverse Reaction**
- C. Suspected Medication(s)**
- D. Reporter Details**



SUSPECTED ADVERSE DRUG REACTION REPORTING FORM

For VOLUNTARY reporting of Adverse Drug Reactions by Healthcare Professionals

INDIAN PHARMACOPOEIA COMMISSION							FOR AMC/NCC USE ONLY				
(National Coordination Centre-Pharmacovigilance Programme of India) Ministry of Health & Family Welfare, Government of India Sector-23, Raj Nagar, Ghaziabad-201002							AMC Report No. _____				
Report Type <input type="checkbox"/> Initial <input type="checkbox"/> Follow up							Worldwide Unique No. : _____				
A. PATIENT INFORMATION							12. Relevant tests/ laboratory data with dates				
1. Patient Initials _____		2. Age at time of Event or Date of Birth _____		3. M <input type="checkbox"/> F <input type="checkbox"/> Other <input type="checkbox"/>							
					4. Weight _____ Kgs						
B. SUSPECTED ADVERSE REACTION							13. Relevant medical/ medication history (e.g. allergies, race, pregnancy, smoking, alcohol use, hepatic/renal dysfunction etc.)				
5. Date of reaction started (dd/mm/yyyy)							14. Seriousness of the reaction: No <input type="checkbox"/> if Yes <input type="checkbox"/> (please tick anyone)				
6. Date of recovery (dd/mm/yyyy)											
7. Describe reaction or problem											
							<input type="checkbox"/> Death (dd/mm/yyyy) <input type="checkbox"/> Congenital-anomaly <input type="checkbox"/> Life threatening <input type="checkbox"/> Required intervention to Prevent permanent impairment/damage <input type="checkbox"/> Hospitalization/Prolonged <input type="checkbox"/> Disability <input type="checkbox"/> Other (specify)				
							15. Outcomes				
							<input type="checkbox"/> Recovered <input type="checkbox"/> Recovering <input type="checkbox"/> Not recovered <input type="checkbox"/> Fatal <input type="checkbox"/> Recovered with sequelae <input type="checkbox"/> Unknown				
C. SUSPECTED MEDICATION(S)											
S.No	8. Name (Brand/Generic)	Manufacturer (if known)	Batch No. / Lot No.	Exp. Date (if known)	Dose used	Route used	Frequency (OD, BD etc.)	Therapy dates		Indication	Causality Assessment
								Date started	Date stopped		
i											
ii											
iii											
iv											
S.No as per C	9. Action Taken (please tick)						10. Reaction reappeared after reintroduction (please tick)				
	Drug withdrawn	Dose increased	Dose reduced	Dose not changed	Not applicable	Unkn own	Yes	No	Effect unknown	Dose (if reintroduced)	
i											
ii											
iii											
iv											
11. Concomitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction)											
S.No	Name (Brand/Generic)	Dose used	Route used	Frequency (OD, BD, etc.)	Therapy dates		Indication				
					Date started	Date stopped					
i											
ii											
iii											
Additional Information:							D. REPORTER DETAILS				
							16. Name and Professional Address: _____				
							Pin: _____ E-mail _____				
							Tel. No. (with STD code) _____ Occupation: _____ Signature: _____				
							17. Date of this report (dd/mm/yyyy): _____				
Confidentiality: The patient's identity is held in strict confidence and protected to the fullest extent. Programme staff is not expected to and will not disclose the reporter's identity in response to a request from the public. Submission of a report does not constitute an admission that medical personnel or manufacturer or the product caused or contributed to the reaction.											

Casulity Assessment

Causality assessment is defined as “the evaluation of the likelihood that a medicine OR drug was the causative agent of an observed adverse reaction”

Causality Assessment committee:

Assess the causal relationship between drug and adverse reaction.

PHARMACOVIGILANCE COMMITTEE

- Evaluate ADR reports.
- Take necessary steps for reporting of ADRs.
- Ensures timely submission of reported ADRs to National Coordinating Centre.
- Close monitoring of drugs causing Serious ADR's.
- Withdrawal of the suspected medication throughout the hospital (in extreme cases).
- Taking preventive measures (in case of definitively preventable ADR's).
- Informing to the regulatory authority.

EVIDENCES

- Documented definition of ADR, IN APEX MANUAL, ADR Reporting forms
- Evidence for analysis, Corrective action, Preventive action
- Training records,
- Staff Interview

THANK YOU